Cargando…
A treat and extend protocol with Aflibercept for cystoid macular oedema secondary to central retinal vein occlusion – an 18-month prospective cohort study
BACKGROUND: To evaluate the safety and efficacy of a treat-and-extend protocol of aflibercept for cystoid macular oedema (CMO) secondary to central retinal vein occlusion (CRVO). METHODS: Twenty patients with CMO secondary to CRVO were included in this prospective cohort study. After 3 loading 4-wee...
Autores principales: | O’Day, Roderick, Ali, Noha, Lim, Lyndell L., Sandhu, Sukhpal, Chau, Thuy, Wickremasinghe, Sanjeewa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7038604/ https://www.ncbi.nlm.nih.gov/pubmed/32093666 http://dx.doi.org/10.1186/s12886-020-01346-8 |
Ejemplares similares
-
Real-world outcomes of intravitreal bevacizumab treat-and-extend for cystoid macular oedema secondary to central retinal vein occlusion
por: Gildea, David, et al.
Publicado: (2023) -
Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO)
por: Cornish, E. E., et al.
Publicado: (2023) -
Prospective exploratory study to assess the safety and efficacy of aflibercept in cystoid macular oedema associated with retinitis pigmentosa
por: Strong, Stacey A, et al.
Publicado: (2020) -
Efficacy of a Modified Treat-and-Extend Aflibercept Regimen for Macular Oedema in Eyes with Central Retinal Vein Occlusion: 2-Year Prospective Study
por: Arai, Yusuke, et al.
Publicado: (2023) -
Comment on: Ranibizumab and aflibercept intravitreal injection for treatment
naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)